Premier Pharmacy Labs is voluntarily recalling multiple products because of the potential lack of sterility assurance.
Premier Pharmacy Labs announced on April 11, 2018 that it was voluntarily recalling products because of a potential lack of sterility assurance. The recall was initiated after the company detected microbial contamination during routine testing of subsequent unreleased product lots. An interaction between the product syringe and tamper-evident container closure was found. The company stated in a press release that this interaction may result in the potential introduction of microorganisms.
While the company has not yet received any complaints about adverse events, it warns that use of “non-sterile injection products that are intended to be sterile may result in a site-specific or systemic infection, which in turn may cause hospitalization, significant morbidity (permanent organ damage), or a fatal outcome.”
Products affected by the recall, which were distributed nationwide to hospital pharmacies, clinics, and healthcare facilities, include the following:
More product information, including lot numbers and beyond use dates, can be found on FDA’s website.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.